VA study maps Real-World use of prostate cancer drug
NCT ID NCT06462014
First seen Dec 12, 2025 · Last updated May 12, 2026 · Updated 18 times
Summary
This study looked at medical records of 507 veterans with prostate cancer who started taking relugolix between 2020 and 2023. Researchers wanted to understand who these patients were, what other treatments they had received, and where they lived. The goal was to describe real-world use of this hormone-blocking drug, not to test if it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.